Although BCR–ABL inhibitor based treatment helps majority of CML patients to lead normal life till treatment continue but unfortunately few patients i.e. 20-30% develop TKI resistance, either primary or secondary and are prone to progress toward the AP or BP of the disease (Kang et al., 2006). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.